Ilex Capital Partners’s Pfizer PFE Stock Holding History

Ilex Capital Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-118,007	Closed	-$2.99M	–	237
2025 Q1	$2.99M	Buy	+118,007	New	+$3.09M	0.12%	54

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Ilex Capital Partners's PFE Position: Q2 2025 in Review

Ilex Capital Partners sold out of Pfizer (PFE) in Q2 2025, closing a stake of 118,007 shares — an estimated $2.99M sold.

Ilex Capital Partners first reported a position in PFE in Q1 2025 and held it in 1 quarter. The position peaked at $2.99M in Q1 2025. 2,810 funds tracked by Wall St. Rank hold PFE as of Q2 2025.

Ilex Capital Partners reported no remaining Pfizer position as of Q2 2025 after selling out during the quarter.
Ilex Capital Partners sold 118,007 Pfizer shares in Q2 2025, an estimated $2.99M.
Ilex Capital Partners first reported a position in Pfizer in Q1 2025 and held it in 1 quarter.
Ilex Capital Partners's Pfizer position peaked at $2.99M in Q1 2025.
2,810 funds tracked by Wall St. Rank held Pfizer as of Q2 2025.

Based on Ilex Capital Partners's 13F filing for Q2 2025, filed 14 Aug 2025.